Because ACEi and ARBs are known to upregulate ACE2 mRNA level [7], it has been suggested that these therapies can theoretically increase the risk of SARS- CoV-2 infection and cause more severe COVID-19 owing to the role of ACE2 as the viral binding site [2]. This evidence concerns the gene ACE2 and COVID-19.